We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Rua Life Sciences Plc | LSE:RUA | London | Ordinary Share | GB0033360586 | ORD 5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 2.25% | 11.375 | 10.75 | 12.00 | 11.375 | 11.125 | 11.13 | 90,931 | 08:24:24 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Plastics,resins,elastomers | 2.18M | -2M | -0.0323 | -3.52 | 7.06M |
Date | Subject | Author | Discuss |
---|---|---|---|
25/10/2021 14:05 | Investor presentation on the 3rd. Hopefully some news drops in prior. | jordanbmz | |
20/10/2021 08:16 | Thanks someuwin. Good to see Biomerics actively marketing Elast-Eon via its “Quadra” brand. | bones | |
19/10/2021 23:14 | Tweet just out... Biomerics @Biomerics -2m Biomerics offers multiple silicone copolymer chemistries to support medical device development. Contact us to learn more about Quadrasil, EcSil, and Elast-Eon! Visit - #materials #polyurethanes #chemistry #implantables #technology #medicaldevices | someuwin | |
19/10/2021 22:56 | They were anticipating “clinical and industry reaction” to their presentation at EACTS. Has anyone got any insight into the reaction if any.? The paper was also to be published in a journal - I guess they will have that to announce soon. And the 510k submission to cap it all. | unionhall | |
19/10/2021 20:12 | A board presentation is scheduled for 3 Nov and, last year, there was a big update on 23 Oct 20, so I think one could be due over the next few days? | bones | |
18/10/2021 10:02 | Very tight spread offer at 1.68 and bid 1.65. MMs want your stock. | nimbo10 | |
18/10/2021 09:40 | Current price is anything but weak, long may it continue... gla | andyview | |
18/10/2021 09:36 | We know there’s a presentation on 3rd November to go over everything from EACTS and the vascular business generally. I assume something will precede that. Hopefully that will include the submission of the 510k application to the FDA. The next RNS might therefore be a general Vascular Update including EACTS info? | bones | |
18/10/2021 09:22 | Keeping it back just in case it is needed to counter weakening of the SP? | semper vigilans | |
18/10/2021 08:41 | Disappointing not to have an RNS now the EACTS meeting (13-16 October 2021) has finished if there was a presentation there on in vivo testing that will lead to "a potentially seminal paper". What was said about the in vivo testing? Anything new or new data, if so it should be RNS'd? If not and if it was just what we know already, then the last RNS dealing with this was a bit of a puff piece. | sicilian_kan | |
14/10/2021 15:48 | The PDF available on the EACTS website is not the “potentially seminal paper” referred to, that is certain. They are probably just the slides for background. What gets said at the talk is the key and then the surgeons can get talking. I don’t know that any “potentially seminal paper” has yet been published? | bones | |
14/10/2021 15:16 | They are obviously shaking it. Still getting offered over 162 on bid | mikeh30 | |
14/10/2021 15:03 | Nope - the paper to be presented is already in the public domain and so any related RNS would have been issued by now. | toffeeman | |
14/10/2021 14:44 | I guess perhaps on update rns 1st thing is quite possible then. | cocker | |
14/10/2021 14:24 | The EACTS presentation appears to be set for 08.42 tomorrow (Friday 15th): Click the Friday tab, scroll to 08.15 - 09.45 session called “Searching for options to improve the aortic treatment” and head for the 08.42 item. There is a PDF of the presentation with graphic pictures of a sheep operation, should you be interested! | bones | |
14/10/2021 14:18 | Singer joined as a new market maker this week and has been busy on the bid these last two days. Make of that what you will. | bones | |
14/10/2021 13:37 | Selling 162.5 (that's above offer) buying 164 (slightly below offer) Halifax. | wageslave | |
14/10/2021 13:33 | I think they are trying every trick they can to fill an order as buying would be a lot easier if there was free stock. | wageslave | |
14/10/2021 13:27 | Has anyone else noticed strange trading action by the MMs? There is regular buying coming in but the MMs keep lowering the bid. Either there is a large sell that they are holding back or they are intentionally widening the spread in an attempt to reduce buying but it isn't working. If they are trying to lower the bid to reduce buying due to low stock then they are going to get themselves into difficulty because they must be going short to cover themselves. | cfb2 | |
14/10/2021 13:24 | They dropped the price to 153 earlier to pick up stock. Checkd this as you can't buy over 5k unless you opt for a negotiated trade. Bodes well. | wageslave | |
13/10/2021 17:36 | Long term chart getting me excited. I’d expect to run into a bit of supply over the next 20 or 30p but given the pipeline of news this should be mild turbulence. | greedy rooster | |
13/10/2021 16:03 | Been looking good here for a few days now, long may it continue.. gla | andyview | |
13/10/2021 13:52 | Well I am doing my level best as just picked up another 5000 | cocker | |
13/10/2021 11:05 | These are still 150p bid, charts looks like they can't wait to jump. | greedy rooster | |
12/10/2021 11:42 | If that is correct, Mike, then yes. I have updated the header with RUA’s analysis of substantial shareholders at 9th September 2021 per their website but adjusted for the subsequent Walker Crips change per Marketscreener.com. EDIT on 13/10/21: I am informed by a reliable source that the marketscreener data is not correct in this case and that the Amati “addition̶ | bones |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions